Novogen Limited (ASX:NRT)
will expand its board to 6 members with the addition of US based directors Bryce Carmine and Ian Phillips.
The biotechnology company is entering a significant growth phase and needed to bring specific skill-sets to the board table.
Bryce Carmine has over 30 years experience in global pharmaceuticals including late stage drug development pipelines.
Ian Phillips brings a wealth of banking, economic modelling and financial planning experience to the drug company.
Novogen made a net loss of $2.4 million for the first six months of the 2015 financial year.